| |
Latest 10 SEC filings (by transaction date) for ASRT within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 9/24 | Apr 9/24 | Kirk Sigurd | Direct Ownership | Stock Option (right to buy) | Form 3 : Initial Statement of Beneficial Ownership of Securities | ||
Mar 15/24 | Mar 14/24 | Tyree James L | Direct Ownership | Common Stock | S - Open market or private sale | -10,251 | $1.12 |
Feb 23/24 | Feb 21/24 | Schlessinger Sam | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -17,151 | |
Feb 23/24 | Feb 21/24 | Schlessinger Sam | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -8,506 | $0.790 |
Feb 23/24 | Feb 21/24 | Schlessinger Sam | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 17,151 | |
Feb 23/24 | Feb 21/24 | Schwichtenberg Paul | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -17,151 | |
Feb 23/24 | Feb 21/24 | Schwichtenberg Paul | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -8,506 | $0.790 |
Feb 23/24 | Feb 21/24 | Schwichtenberg Paul | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 17,151 | |
Feb 23/24 | Feb 21/24 | Patel Ajay | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -17,151 | |
Feb 23/24 | Feb 21/24 | Patel Ajay | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -8,506 | $0.790 |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for ASRT within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 9/24 | Apr 9/24 | Kirk Sigurd | Direct Ownership | Stock Option (right to buy) | Form 3 : Initial Statement of Beneficial Ownership of Securities | ||
Mar 15/24 | Mar 14/24 | Tyree James L | Direct Ownership | Common Stock | S - Open market or private sale | -10,251 | $1.12 |
Feb 23/24 | Feb 21/24 | Schlessinger Sam | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -17,151 | |
Feb 23/24 | Feb 21/24 | Schlessinger Sam | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -8,506 | $0.790 |
Feb 23/24 | Feb 21/24 | Schlessinger Sam | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 17,151 | |
Feb 23/24 | Feb 21/24 | Schwichtenberg Paul | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -17,151 | |
Feb 23/24 | Feb 21/24 | Schwichtenberg Paul | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -8,506 | $0.790 |
Feb 23/24 | Feb 21/24 | Schwichtenberg Paul | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 17,151 | |
Feb 23/24 | Feb 21/24 | Patel Ajay | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -17,151 | |
Feb 23/24 | Feb 21/24 | Patel Ajay | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -8,506 | $0.790 |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Eyepoint Pharmaceuticals (OQ:EYPT) |
AbbVie (N:ABBV) |
Merck & Co (N:MRK) |